Stable coronary disease
Conditions
Interventions
Control:none
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-90 years; 2.Clinical diagnosis of stable coronary artery disease; 3.Successful implantation of at least one coronary drug-eluting stent; 4.Receiving dual antiplatelet therapy (aspirin + clopidogrel) after PCI; 5.Willing to participate in the study.
Exclusion criteria
Exclusion criteria: 1.Scheduled for surgery requiring discontinuation of antiplatelet therapy within the next 6 months; 2.Life expectancy <1 year; 3.Known intolerance or allergy to aspirin, clopidogrel, or non-steroidal anti-inflammatory drugs (NSAIDs); 4.History of intracranial hemorrhage; 5.History of ischemic stroke within the past 6 months; 6.Active bleeding; 7.Known hematologic disorders; 8.Platelet count <100×10^9/L; 9.Hemoglobin <90 g/L; 10.Known malignant tumors; 11.Concurrent use of oral anticoagulants; 12.Participation in other interventional clinical studies; 13.Investigator deems the patient unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a composite of cardiac death, non-fatal MI,ischemic stroke, unplanned revascularization or stent thrombus; | — |
Secondary
| Measure | Time frame |
|---|---|
| High Residual Platelet Reactivity (MAadp>47mm);periprocedural myocardial infarction; | — |
Countries
China
Contacts
Public ContactHongyi Wu
Zhongshan Hospital, Fudan University
Outcome results
None listed